Latest Regulatory News

Lithium Plus Minerals reports key regulatory and environmental milestones for its Lei Lithium Development Project, progressing towards a near-term direct shipped ore operation backed by a strategic partnership with Canmax Technologies.

Elsight Limited reports record-breaking revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market opportunities, positioning the company for profitability later this year.

Elsight Limited reports a record 340% revenue surge to US$4.8 million in the first half of 2025, backed by a robust US$11.45 million contract backlog and a strategic A$60 million capital raise to fuel expansion.

Peregrine Gold has announced a major discovery of a high-grade Channel Iron Deposit spanning over 7.7km near established BHP iron ore operations in Western Australia, signaling a promising new chapter for the Newman Gold Project.

Woodside Energy reported a 2% rise in quarterly production and lowered unit costs, while the Louisiana LNG Project’s final investment decision and a major Stonepeak partnership unlock significant future value.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Paladin Energy reports a 33% production surge at its Langer Heinrich Mine alongside a key environmental milestone for its Canadian project and announces a new CEO appointment. The company outlines strong FY2026 guidance amid ongoing operational ramp-up.

Alligator Energy reports a 10% increase in indicated uranium resources at its Samphire Project, secures a $17.25 million capital raise, and announces a CEO transition as it advances key uranium exploration and development milestones.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Astron Corporation has released updated economics for its Donald Rare Earth and Mineral Sands Project, showcasing robust financial metrics and targeting a Final Investment Decision by late 2025 with production slated for 2027.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.